78 related articles for article (PubMed ID: 21427551)
21. Pharmacogenetics and breast cancer management: current status and perspectives.
Ciccolini J; Fanciullino R; Serdjebi C; Milano G
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):719-29. PubMed ID: 25690018
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics in colorectal cancer: a systematic review.
Funke S; Brenner H; Chang-Claude J
Pharmacogenomics; 2008 Aug; 9(8):1079-99. PubMed ID: 18681783
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.
Moradi-Marjaneh R; Khazaei M; Seifi S; Hassanian SM; Ferns GA; Avan A
Curr Pharm Des; 2018; 24(23):2710-2718. PubMed ID: 30051785
[TBL] [Abstract][Full Text] [Related]
24. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers.
Bignucolo A; Scarabel L; Toffoli G; Cecchin E; De Mattia E
Expert Rev Clin Pharmacol; 2022 Jun; 15(6):689-713. PubMed ID: 35829762
[TBL] [Abstract][Full Text] [Related]
25. Current pharmacogenetics in colorectal cancer--do they have an impact on our clinical treatment strategies?
Goekkurt E; Stoehlmacher J
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):577-8. PubMed ID: 16372523
[No Abstract] [Full Text] [Related]
26. New paradigms in the treatment of breast and colorectal cancer--an introduction.
Kaye S
Eur J Cancer; 2002 Feb; 38 Suppl 2():1-2. PubMed ID: 11841928
[No Abstract] [Full Text] [Related]
27. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
28. Integrated patient and tumor genetic testing for individualized cancer therapy.
Hertz DL; McLeod HL
Clin Pharmacol Ther; 2016 Feb; 99(2):143-6. PubMed ID: 26537014
[TBL] [Abstract][Full Text] [Related]
29. Challenges in pharmacogenetics.
Cascorbi I; Bruhn O; Werk AN
Eur J Clin Pharmacol; 2013 May; 69 Suppl 1():17-23. PubMed ID: 23640184
[TBL] [Abstract][Full Text] [Related]
30. Minimum information required for a DMET experiment reporting.
Kumuthini J; Mbiyavanga M; Chimusa ER; Pathak J; Somervuo P; Van Schaik RH; Dolzan V; Mizzi C; Kalideen K; Ramesar RS; Macek M; Patrinos GP; Squassina A
Pharmacogenomics; 2016 Sep; 17(14):1533-45. PubMed ID: 27548815
[TBL] [Abstract][Full Text] [Related]
31. The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Song Q; Zhou X; Yu J; Dong N; Wang X; Yang H; Ren J; Lyerly HK
Sci Rep; 2015 Nov; 5():16775. PubMed ID: 26602960
[TBL] [Abstract][Full Text] [Related]
32. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
Clarke JD; Hardwick RN; Lake AD; Canet MJ; Cherrington NJ
J Pharmacol Exp Ther; 2014 Mar; 348(3):452-8. PubMed ID: 24403518
[TBL] [Abstract][Full Text] [Related]
33. Patterns of cancer genetic testing: a randomized survey of Oregon clinicians.
Cox SL; Zlot AI; Silvey K; Elliott D; Horn T; Johnson A; Leman RF
J Cancer Epidemiol; 2012; 2012():294730. PubMed ID: 23150730
[TBL] [Abstract][Full Text] [Related]
34. Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
Jiang WQ; Fu FF; Li YX; Wang WB; Wang HH; Jiang HP; Teng LS
J Zhejiang Univ Sci B; 2012 Sep; 13(9):663-75. PubMed ID: 22949358
[TBL] [Abstract][Full Text] [Related]
35. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?
Crona D; Innocenti F
Biomark Med; 2012 Jun; 6(3):349-62. PubMed ID: 22731909
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
O'Donnell PH; Stadler WM
Clin Cancer Res; 2012 May; 18(10):2809-16. PubMed ID: 22427349
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Dong N; Yu J; Wang C; Zheng X; Wang Z; Di L; Song G; Zhu B; Che L; Jia J; Jiang H; Zhou X; Wang X; Ren J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1197-203. PubMed ID: 22426923
[TBL] [Abstract][Full Text] [Related]
38. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
O'Donnell PH; Ratain MJ
Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomic contribution to drug response.
Watson RG; McLeod HL
Cancer J; 2011; 17(2):80-8. PubMed ID: 21427551
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
